Our President and CEO John Lu was recently interviewed by IMAPAC on key developments, technologies and challenges in Asia's Cell and Gene Therapy Industry. You can find the full interview in the PDF attached.
Proteintech and HebeCell announce their collaborative partnership to develop proprietary nanobody based chimeric antigen receptor (nCAR) technology for the development and commercialization of iPSC-derived natural killer (iPSC-nCAR-NK) cells, a promising cellular immunotherapy treatment for cancer and other diseases.